{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["parsaclisib","ruxolitinib"]],"indication":"myelofibrosis with suboptimal response to ruxolitinib","name":"LIMBER-304","nct_id":"NCT04551053","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=limber-304-nct04551053. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants will receive parsaclisib starting from Day 1 for the duration of study, while continuing to receive the stable dose of ruxolitinib they were taking for the 8 weeks prior to Day 1.","label":"Group A : ruxolitinib +parsaclisib","type":"EXPERIMENTAL"},{"description":"Participants will receive placebo starting from Day 1 for the duration of study, while continuing to receive the stable dose of ruxolitinib they were taking for the 8 weeks prior to Day 1.","label":"Group B : ruxolitinib + placebo","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2024-08-21","type":"ACTUAL"},"conditions":["Myelofibrosis","Primary Myelofibrosis","Post Essential Thrombocythemia Myelofibrosis","Post Polycythemia Vera Myelofibrosis"],"enrollment":{"count":177,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"parsaclisib","otherNames":["INCB050465"],"type":"DRUG"},{"name":"ruxolitinib","otherNames":["Jakafi","Jakavi"],"type":"DRUG"},{"name":"placebo","otherNames":[],"type":"DRUG"}],"last_update":"2025-10-02","lead_sponsor":"Incyte Corporation","official_title":"A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kδ Inhibitor Parsaclisib Plus Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib","overall_status":"TERMINATED","phases":["PHASE3"],"primary_completion_date":{"date":"2023-08-16","type":"ACTUAL"},"primary_outcomes":[{"measure":"Percentage of Participants Achieving ≥25% Reduction in Spleen Volume From Baseline to Week 24 as Measured by Magnetic Resonance Imaging (MRI) (or Computed Tomography [CT] Scan in Applicable Participants)","timeFrame":"Baseline; Week 24"}],"references":[],"start_date":{"date":"2021-05-26","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)","url":"https://clinicaltrials.gov/study/NCT04551053"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/limber-304-nct04551053"}